UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC File
Number: 000-53127
CUSIP
Number: 35702Q109
|
(CHECK
ONE):
|
o Form
10-K
|
o Form
20-F
|
o Form
11-K
|
ýForm
10-Q
|
o Form
10-D
|
||||
|
o Form
N-SAR
|
o Form
N-CSR
|
|
For
Period Ended: September 30, 2010
|
||||||||||
|
o Transition Report
on Form 10-K
|
||||||||||
|
o Transition Report
on Form 20-F
|
||||||||||
|
o Transition Report
on Form 11-K
|
||||||||||
|
o Transition Report
on Form 10-Q
|
||||||||||
|
o Transition Report
on Form N-SAR
|
||||||||||
|
For
the Transition Period
Ended:
|
|
Read
Instruction (on back page) Before Preparing Form. Please Print or
Type.
|
|
Nothing
in this form shall be construed to imply that the Commission has verified
any information
contained
herein.
|
|
If
the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
N/A
|
PART
I - REGISTRANT INFORMATION
|
Genesis
Biopharma, Inc.
|
|
Full
Name of Registrant
|
|
Freight
Management Corp.
|
|
Former
Name if Applicable
|
|
1601
N. Sepulveda Blvd., #632
|
|
Address
of Principal Executive Office (Street and Number)
|
|
Manhattan
Beach, California 90266
|
|
City,
State and Zip Code
|
PART
II - RULES 12b-25 (b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
|
ý
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report or transition report on Form
10-Q or subject distribution report on Form 10-D, or portion thereof, will
be filed on or before the fifth calendar day following the prescribed due
date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART
III - NARRATIVE
State
below in reasonable detail why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR,
or the transition report or portion thereof, could not be filed within the
prescribed time period.
Completion
of the company’s financial statements has been delayed due to a delay in the
review of the valuation of derivative liabilities.
PART
IV - OTHER INFORMATION
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|
Richard
McKilligan
|
(866)
|
963-2220
|
||
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If answer
is no, identify report(s).
|
|
ý Yes o
No
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
|
|
ý Yes o
No
|
|
|
The company anticipates that the
inclusion in the company’s Statements of Operations of the fair value of
the derivative liability being valued will result in a significantly
larger net loss for the periods presented as compared to the corresponding
periods for the last fiscal year. For the three and nine-month periods
ended September 30, 2009, the company previously reported net losses of
$3,470 and $13,427, respectively. In comparison, for the comparable 2010
periods, the company expects to report net losses of approximately
$713,757 and $866,066,
respectively.
|
|
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
|
Genesis
Biopharma, Inc.
|
|
(Name
of Registrant as Specified in
Charter)
|
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Date:
November 16, 2010
|
/s/
Richard McKilligan
|
|
Richard
McKilligan, Chief Financial Officer
|
INSTRUCTION: The form may be
signed by an executive officer of the registrant or by any other duly authorized
representative. The name and title of the person signing the form shall be typed
or printed beneath the signature. If the statement is signed on behalf of the
registrant by an authorized representative (other than an executive officer),
evidence of the representative’s authority to sign on behalf of the registrant
shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See
18 U.S.C. 1001).